Article1 min read·Published Jun 2026

Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience

Part of Short Bowel Syndrome & Intestinal Failure 8 items

pubmed.ncbi.nlm.nih.gov

Michael Helmrath

Background: Short bowel syndrome-associated intestinal failure (SBS-IF) requires long-term parenteral nutrition (PN), increasing the risk of complications such as central line associated bloodstream infections, sepsis and liver disease. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, has been shown to enhance intestinal adaptation and reduce PN dependence, but long-term real-world data in children are limited. Objectives: To describe the medium-term clinical outcomes and safety profile of teduglutide treatment in children with short bowel syndrome-associated intestinal failure (SBS-IF). Methods: A retrospective cohort study was conducted at a single tertiary center. There were 41 children with SBS-IF treated with Teduglutide among the 161children who were managed at the center between 2018 and 2022. Data on PN requirements, growth parameters, and treatment duration were analyzed. The time to PN weaning was assessed using a Cox proportional hazards model. Results: At a median follow-up of 29.2 months, 21 patients (51.2%) were successfully weaned off PN, and 24 patients (65%) achieved at least a 20% reduction in PN requirements. The median time to complete PN weaning was 7.3 months. Baseline variables associated with time to PN discontinuation included the percentage of PN-derived calories at treatment initiation and residual small bowel length. No treatment-related adverse events were reported, although 12% of patients required increased PN support over time. Conclusion

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jun 2026 · 1 min read

In brief

Single-center study of 41 children with short bowel syndrome-associated intestinal failure treated with teduglutide showed 51% achieved complete parenteral nutrition independence at median 7.3 months, with 65% reducing PN requirements by at least 20%. Treatment was well-tolerated with no adverse events, supporting teduglutide's role in intestinal rehabilitation for pediatric SBS-IF patients.

Written by the GCMD Library team from the article.

Michael Helmrath

Statements in this article

Short bowel syndrome-associated intestinal failure requires long-term parenteral nutrition, increasing the risk of complications such as central line associated bloodstream infections, sepsis and liver disease.
EstablishedBackground
Teduglutide, a glucagon-like peptide-2 analog, has been shown to enhance intestinal adaptation and reduce parenteral nutrition dependence.
EstablishedBackground
Among 161 children with short bowel syndrome-associated intestinal failure managed at the center between 2018 and 2022, 41 were treated with teduglutide.
ResearchMethods
At a median follow-up of 29.2 months, 21 patients (51.2%) were successfully weaned off parenteral nutrition.
ResearchResults
24 patients (65%) achieved at least a 20% reduction in parenteral nutrition requirements.
ResearchResults
The median time to complete parenteral nutrition weaning was 7.3 months.
ResearchResults
Baseline variables associated with time to parenteral nutrition discontinuation included the percentage of PN-derived calories at treatment initiation and residual small bowel length.
ResearchResults
No treatment-related adverse events were reported.
ResearchResults
12% of patients required increased parenteral nutrition support over time.
ResearchResults